Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biovest International, a majority-owned subsidiary of Accentia Biopharmaceuticals, has secured the worldwide, exclusive license to Revimmune for the treatment and prevention of transplant rejection including rejection following a bone marrow transplant.
Subscribe to our email newsletter
As an initial indication, the company intends to submit an investigational new drug (IND) application seeking FDA permission to enter a Phase III clinical trial of Revimmune usage in bone marrow transplants to treat and possibly cure sickle cell anemia.
The technology is being licensed to Biovest for transplant rejection from Revimmune, LLC, a Hopkins Capital Group II portfolio company, which holds the exclusive license for the technology from the Johns Hopkins University. Revimmune, LLC, has previously licensed the exclusive, worldwide rights to Revimmune for treatment of all autoimmune diseases to Accentia Biopharmaceuticals.